Nektar Therapeutics (NKTR) : Traders are bullish on Nektar Therapeutics (NKTR) as it has outperformed the S&P 500 by a wide margin of 13.12% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.61%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.58% in the last 1 week, and is up 13.55% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Nektar Therapeutics is up 24.71% in the last 3-month period. Year-to-Date the stock performance stands at 2.43%. The stock has recorded a 20-day Moving Average of 2.03% and the 50-Day Moving Average is 9.73%.
Nektar Therapeutics (NASDAQ:NKTR): The stock opened at $17.70 on Friday but the bulls could not build on the opening and the stock topped out at $17.74 for the day. The stock traded down to $17.15 during the day, due to lack of any buying support eventually closed down at $17.26 with a loss of -2.60% for the day. The stock had closed at $17.72 on the previous day. The total traded volume was 806,133 shares.
Nektar Therapeutics is a clinical-stage biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. The Companys pipeline is comprised of drug candidates for therapeutic areas, including oncology, pain, anti-infectives, and immunology. The Companys research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Its polymer chemistry platform is being used to create specialized therapeutics, including small molecule oral and parenteral drugs, proteins, peptides and antibody fragments.